Yes, you can develop atherosclerosis with completely normal cholesterol levels. While high LDL cholesterol is one of the most well-known drivers of plaque buildup in arteries, it is far from the only one. Roughly 15% of patients hospitalized for acute coronary events in one large study had normal LDL cholesterol at the time of admission. The disease is more complex than a single number on a blood test, and understanding the other forces at work can help you spot risk factors your standard lipid panel might miss.
Why Normal Cholesterol Doesn’t Guarantee Clean Arteries
Atherosclerosis begins with damage to the inner lining of your blood vessels, called the endothelium. Once that lining is injured, cholesterol particles can slip into the artery wall and trigger a cascade of inflammation and plaque formation. High LDL cholesterol makes this process more likely, but the initial damage can come from several sources that have nothing to do with cholesterol: high blood pressure, diabetes, smoking, and chronic inflammation all injure the endothelium on their own. Research from Cedars-Sinai confirms that endothelial dysfunction precedes atherosclerosis and can result from any of these factors independently.
Think of it this way: cholesterol is the building material of plaque, but the construction project starts with a wound in the artery wall. If something else creates that wound, even modest amounts of cholesterol circulating in your blood can accumulate over time.
Inflammation as an Independent Driver
Chronic, low-grade inflammation may be the most underappreciated cause of atherosclerosis in people with normal cholesterol. A blood marker called high-sensitivity C-reactive protein (hs-CRP) measures this kind of systemic inflammation, and it turns out to be a powerful predictor of heart disease on its own.
In a comparative study of patients with ischemic heart disease versus healthy controls, hs-CRP levels were significantly elevated in heart disease patients, while LDL cholesterol differences between the two groups were not statistically significant. Among the heart disease patients, 82% had hs-CRP levels above 3 mg/L, a threshold associated with high cardiovascular risk. The implication is striking: inflammation tracked with the disease far more reliably than cholesterol did in that population.
This isn’t just an academic finding. Patients who have already had a heart attack and are taking cholesterol-lowering medication still face recurrent events at rates up to 60% higher when their hs-CRP remains at or above 2 mg/L, regardless of how well their LDL is controlled. Researchers call this “residual inflammatory risk,” and a landmark trial showed that directly targeting inflammation with an anti-inflammatory drug reduced cardiovascular events by 15% in patients already on statins. The disease kept progressing not because of cholesterol, but because of ongoing inflammation.
Insulin Resistance and Blood Sugar Problems
Insulin resistance, the metabolic dysfunction behind type 2 diabetes and prediabetes, damages arteries through a mechanism that operates independently of your lipid levels. Normally, insulin signaling in the cells lining your blood vessels triggers protective responses: it helps arteries relax, increases blood flow, and reduces the stickiness that allows white blood cells to latch onto vessel walls. When those cells become resistant to insulin, these protective effects shut down.
Animal studies published in Cell Metabolism demonstrated that when insulin signaling was knocked out in blood vessel lining cells, the arteries lost their ability to dilate properly, and white blood cells began adhering to vessel walls at increased rates. This is the opening act of atherosclerosis, and it happened without any change in cholesterol. In people with insulin resistance, the pathway that produces the vessel-relaxing compound nitric oxide gets suppressed, while pathways that promote inflammation and cell growth remain active or even ramp up. The result is stiffer, more inflamed arteries primed for plaque development.
This helps explain why people with metabolic syndrome or type 2 diabetes face elevated heart disease risk even when their standard cholesterol numbers look fine.
Lipid Markers Your Standard Panel Misses
A standard cholesterol panel measures LDL cholesterol, HDL cholesterol, and triglycerides. But it does not capture every particle that contributes to plaque. Two markers in particular can be elevated even when LDL looks normal.
Apolipoprotein B
Apolipoprotein B (apoB) is a protein found on every particle capable of embedding in your artery wall. Your LDL number estimates the amount of cholesterol carried by those particles, but it doesn’t count the particles themselves. Some people carry many small, dense LDL particles that collectively hold a normal amount of cholesterol but present a larger number of individual particles to the artery wall. In these cases, LDL cholesterol reads as normal while the actual atherogenic particle count is high.
Data from the UK Biobank found that 18% of participants had a mismatch between their apoB and LDL cholesterol levels. In those people, apoB predicted cardiovascular events, but LDL cholesterol did not. Men, smokers, and people with metabolic syndrome, diabetes, higher body mass index, or elevated triglycerides were most likely to have apoB running higher than their LDL number suggested. The Framingham Heart Study also confirmed that apoB improves risk prediction beyond what LDL cholesterol alone provides.
Lipoprotein(a)
Lipoprotein(a), often written as Lp(a), is a genetically determined particle that behaves like LDL but carries additional risks. It builds up in artery walls the same way LDL does, but it also promotes blood clotting and triggers inflammation that makes existing plaques more likely to rupture. Levels above 50 mg/dL are considered high, and this is common across all racial and ethnic groups, with particularly high prevalence in Black populations.
Because Lp(a) levels are almost entirely determined by your genes, they don’t respond to diet or exercise, and standard cholesterol-lowering medications have limited effect on them. Most importantly, Lp(a) is not included in a routine lipid panel. You have to specifically ask for it. Someone with perfect LDL cholesterol but an Lp(a) of 80 mg/dL could be silently accumulating plaque for decades.
Hypertension and Smoking Damage Arteries Directly
High blood pressure subjects artery walls to chronic mechanical stress. The force of blood pushing against vessel walls, particularly at branch points where arteries divide, physically damages the endothelial lining over time. This shear stress creates the entry points that allow cholesterol and inflammatory cells to infiltrate the artery wall. Research tracking patients with zero coronary calcium (a sign of no detectable plaque) found that high systolic blood pressure was one of the key factors predicting who would develop calcified plaque over time, alongside age and smoking.
Smoking compounds the problem through a different route. Chemicals in cigarette smoke generate oxidative stress that directly poisons endothelial cells, reducing their ability to produce nitric oxide and keep blood vessels flexible. Smoking also makes blood more prone to clotting and increases inflammation. These effects drive atherosclerosis forward with or without elevated cholesterol.
How to Detect Hidden Risk
If your LDL cholesterol is normal but you have other risk factors, a few additional tests can reveal whether atherosclerosis is developing. A coronary artery calcium (CAC) score uses a low-dose CT scan to directly measure calcified plaque in your heart’s arteries. A score of zero is reassuring; any score above zero confirms plaque is present regardless of what your cholesterol says.
An hs-CRP test can identify whether chronic inflammation is putting your arteries at risk. The American Heart Association and American College of Cardiology recognize hs-CRP levels at or above 2.0 mg/L as a risk-enhancing factor that can justify more aggressive preventive treatment, including statin therapy, even in people whose cholesterol is not particularly high. The JUPITER trial specifically enrolled people with LDL cholesterol below 130 mg/dL but hs-CRP at or above 2.0 mg/L and showed that statin treatment reduced their cardiovascular events.
Requesting an apoB measurement and an Lp(a) test rounds out the picture. ApoB above 130 mg/dL is considered a risk-enhancing factor in current guidelines, and a single Lp(a) test in your lifetime is generally enough since the level is genetically fixed. Together, these tests can uncover the risks that a standard cholesterol panel leaves invisible.